FDA-Australia cGMP agreement
Executive Summary
FDA and the Therapeutic Goods Administration of Australia signed a cooperative arrangement Oct. 11 allowing the exchange of information on current Good Manufacturing Practice inspections of human pharmaceutical facilities between the U.S. and Australia. The agreement is part of international harmonization efforts. While this is the first signed agreement, discussions are ongoing with Europe and Japan
You may also be interested in...
CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance
FDA Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, has experience in public health risk assessment that will contribute to the center's revamping of its postmarketing surveillance program.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011